Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Reader Login  

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 265 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   1994| July-September  | Volume 5 | Issue 3  
    Online since June 11, 2008

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Etiopathogenesis of acute poststreptococcal glomerulonephritis
Maha A Azzam, Tej K Mattoo
July-September 1994, 5(3):365-370
The relationship between nephritogenic strains of group A beta-hemolytic streptococci (GABS) and acute poststreptococcal glomerulonephritis (APSGN) is well established. Recent studies have cast some doubts on the importance of the M-antigen which is widely used in classifying the nephritogenic strains of GABS. The renal injury occurs as a result of an immune-mediated process which involves the complement system. This leads to deposition of circulating immune complexes and/or their in-situ formation in the kidney resulting in renal damage. Newer antigenic fractions have been identified in GABS, which include; endostreptocin (ESS), nephritis strain associated protein (NSAP), and pre-absorbing antigen (Pa-Ag). These developments have allowed a better insight into the pathogenesis of APSGN.
  9,517 668 -
Continuous arteriovenous and continuous venovenous haemodialysis
Faissal A.M Shaheen, Iftikhar Ahmed Sheikh, Mohammad Ziad Souqiyyeh
July-September 1994, 5(3):379-383
  7,792 315 -
Treatment of end-stage renal failure in Abu Dhabi, United Arab Emirates
Yassin I El Shahat, Shakuntala Varma, M Zahir Bari, Shah Nawaz, Inderjit Dhawan, Marwan Masry, Kyran Hayes, Avinash Pingle
July-September 1994, 5(3):384-395
  3,952 304 -
The impact of non-HLA factors on renal graft survival
Ahmed Adel Hassan, Essam Mahmoiid Amin, Ahmed Ibrahim Amer, Essam Lotfy Omar, Mohamed Hassan Aly
July-September 1994, 5(3):359-364
Several non-HLA factors such as, age, sex, blood group, and cytomegalovirus (CMV) carrier state of both the donor and the recipient are known to influence renal allograft survival. In a retrospective study on 150 living related donor renal transplant patients, we evaluated the effect of the above mentioned factors on graft survival. Patients were divided into two groups, according to immunosuppression protocols. Group 1 (n=120) patients were on triple therapy with cyclosporin-A, azathioprine and prednisolone whereas those in Group 2 (n=30) were on conventional therapy with azathioprine and prednisolone. In Group 1, the patients aged < 45 years had graft survival rates 100%, 94% and 83% at 1,2 and 3 years, whereas the rates were 87%, 87%, 68% respectively in those aged > 45 years (P < 0.06). Sex of neither the donors nor the recipients affected graft survival. Patients with blood group B had poor graft survival among Group 2 patients (P < 0.05). However, the patients with blood group B in Group 1 had significantly superior graft survival rates than the patients with the same blood group in Group 2 (P < 0.01). No significant difference in the graft survival rates was found between the two groups in relation to other blood groups. Also, there was no significant difference in the graft survival of the CMV negative and the CMV positive (IgG) recipients in both the study groups.
  3,319 197 -
Ten years follow-up of idiopathic focal and segmental glomerulosclerosis
RG Singh, DK Agarwal, Usha , KV Johny, Jaiprakash
July-September 1994, 5(3):354-358
Sixty-four biopsy proven cases of idiopathic focal and segmental glomerulosclerosis (FSGS) were studied retrospectively for 10 years. The mean age of the study patients was 29.5 years and 81.2% of the patients were males. Edema, hematuria, hypertension and azotemia were the main presenting features. All cases were initially treated with steroids alone. Nineteen cases (29.7%) had complete and 14 patients (21.9%) had partial remission while 31 cases (48.4%) had no response. Twenty non-responsive cases were given cyclophosphamide in addition to steroids and seven (35%) patients had complete remission and a similar number had partial remission. Patients who had azotemia, hypertension, nephrotic range proteinuria and diffuse mesangial hypercellularity in addition to segmental sclerosis on renal histology at presentation were classified as malignant FSGS. There were eight such cases of which two showed partial response to steroids. One patient went into complete remission with steroids and cyclophosphamide while two others showed partial remission. Mean duration before the occurrence of renal death in benign FSGS patients was six years while all malignant FSGS cases had renal death within two years. Differentiating benign and malignant FSGS will help in prognostication of patients with this pathology.
  3,049 273 -
Natural progression of calciphylaxis in a patient on haemodialysis
Abraham George, T Timothy Paul, Chandrahasan Kedharnath, Magdy Diwan, Mohammad Ashraf Want, Hla Mon
July-September 1994, 5(3):374-378
A 40 year old patient with end-stage renal disease developed features of calciphylaxis and tumoral calcification after four and half years on regular haemodialysis. The patient had hyperphosphatemia, with high calcium-phosphate index and radiological evidence of hyperparathyroidism before the onset of symptoms. Conservative management was without success and the patient developed florid symptoms. Parathyroidectomy was delayed due to unavoidable circumstances. When it was eventually performed there was a prompt regression of the calcific masses, but not of the vascular calcifications. The natural progression of the disease and its regression by parathyroidectomy provides an interesting insight into this phenomenon, the full blown picture of which is rarely seen these days.
  2,823 235 -
Is erythropoietin safe in haemodialysis patients with multiple myeloma ?
Magdi Hussein, Jacob Mooij, Haysam Roujouleh
July-September 1994, 5(3):371-373
The use of recombinant human erythropoietin (rHuEpo) for the treatment of anemia of end-stage renal disease (ESRD) is now well established. There have also been reports about its use in treating the anemia of other diseases including multiple myeloma (MM). Some concern about the usage of rHuEpo in patients with MM has been raised by studies reporting worsening of myeloma activity after starting this drug. However, other studies have reported its safety in patients with MM. We report here a patient on maintenance haemodialysis, not known to have MM who developed symptoms related to this disease four months after starting rHuEpo. Although we might speculate that the onset of symptoms was coincidental and not causally related to rHuEpo, we recommend close monitoring of the disease activity in patients with MM receiving rHuEpo.
  1,713 187 -
Pediatric renal transplantation: A review of data from north American pediatric renal transplant cooperative study (NAPRTCS)
Paul T McEnery
July-September 1994, 5(3):336-346
  1,465 219 -
Impact of donor source on short-term outcome of renal transplantation in children
Ahmed Bayoomi Shehab, Abdullah Fallatah, Iftikhar Ahmed Sheikh, Mohsen Mohammed Hussein Al-Koussi, Mohamed Salah Gabal, Faissal A.M Shaheen
July-September 1994, 5(3):347-353
Renal transplantation is the ideal renal replacement therapy for children with endstage renal disease (ESRD). Follow-up of pediatric transplant recipients is tedious because of special problems like non-compliance to treatment and a very active immunological status. Twenty-five pediatric patients with ESRD who received kidney transplants in four different centers were followed up at the Jeddah Kidney Center, Saudi Arabia for a mean period of 22 months. The donor source for transplantation was as follows: living related (LR) in seven, cadaveric (CAD) and living unrelated (LUR) in nine patients each. The overall graft survival was 88% and patient survival 100% at the end of the follow-up period. Living related kidney recipients exhibited 100% graft survival at 22 months and also had the best kidney function. All the graft losses were due to irreversible rejection episodes. Medical complications were common and comprised of hypertension (82%), infection (52%) and rejection (44%). Recipients of LR donor kidneys had the lowest incidence of these complications. Surgical problems encountered were few and minor and needed only conservative management. In our experience, children having renal transplantation have an excellent outcome at short-term particularly with LR donors.
  1,293 193 -
Renal transplantation in children
MB Abdurrahman
July-September 1994, 5(3):333-335
  1,098 230 -
  My Preferences